Dr Rodriguez on Treating Patients With Lung Cancer Harboring Multiple Actionable Mutations

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Savolitinib/Osimertinib Yields Responses in EGFR-Mutant, MET-Amplified, Osimertinib-Resistant NSCLC

Novel CAR T-Cell Therapy HR001 Demonstrates Efficacy in R/R Non-Hodgkin Lymphoma

RGI-2001 Plus Tacrolimus/Methotrexate Demonstrates Protective Effect From Acute GVHD Post Allo-HSCT